Implantable Cardioverter Defibrillator Detection During Radiofrequency Catheter Ablation of Ventricular Tachycardia

1996 ◽  
Vol 19 (9) ◽  
pp. 1388-1390 ◽  
Author(s):  
STEFAN HAMMERSCHMIDT ◽  
KEJIANG CAO ◽  
ANSELM SCHAUMANN ◽  
HOLGER KRIEGLSTEIN ◽  
BERND-DIETER GONSKA
2018 ◽  
Vol 28 (6) ◽  
pp. 890-893
Author(s):  
Hisaaki Komaki ◽  
Takashi Nakashima ◽  
Shinya Minatoguchi

AbstractIn some patients with Kawasaki disease, a prior myocardial infarction causes ventricular tachycardia in the chronic post-myocardial infarction phase. We report the case of a 41-year-old man with symptomatic and haemodynamically unstable ventricular tachycardia in whom substrate ablation was performed for the ventricular tachycardia before insertion of an implantable cardioverter-defibrillator.


2020 ◽  
Vol 9 (5) ◽  
pp. 375-385
Author(s):  
Michael E Field ◽  
Laura Goldstein ◽  
Stephanie Hsiao Yu Lee ◽  
Iftekhar Kalsekar ◽  
Paul Coplan ◽  
...  

Aim: To compare outcomes among patients with implantable cardioverter defibrillator/cardiac resynchronization therapy-defibrillator undergoing outpatient ventricular tachycardia (VT) catheter ablation using intracardiac echocardiography (ICE) versus no ICE. Patients & methods: Patients were classified into ICE (n = 1143)/non-ICE (n = 1677) groups based on ICE procedure codes. Patients in each group were propensity matched on study covariates. Survival analyses were used to assess outcomes. To examine residual confounding, falsification outcomes were evaluated. Results: ICE patients had a 24% lower risk of all-cause readmissions, 24% lower risk of cardiovascular-related and 20% lower risk of VT-related readmissions compared with non-ICE patients. Falsification analyses for ICE use association were nonsignificant. Conclusion: Patients with implantable cardioverter defibrillator/cardiac resynchronization therapy-defibrillator undergoing VT ablation with ICE use had significantly lower likelihood of VT-related readmission.


2021 ◽  
pp. 36-42
Author(s):  
Gerald M Lawrie

The treatment of drug-refractory chronic ventricular tachycardia (VT) has undergone a revolution over the last 50 years. We now have automatic implantable cardioverter defibrillator therapy with pace-terminating capabilities, and catheter ablation of VT has refined mapping and improved methods of lesion generation. Between 1980 and 1993, Houston Methodist Hospital became a leader in the diagnosis and surgical ablation of VT and other arrhythmias. This is a brief account of that period and some of the experiences and lessons that have led to significant advances used today.


2014 ◽  
Vol 26 (2) ◽  
pp. 151-157 ◽  
Author(s):  
SANA M. AL-KHATIB ◽  
JAMES P. DAUBERT ◽  
KEVIN J. ANSTROM ◽  
EMILE G. DAOUD ◽  
MARIO GONZALEZ ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document